No Data
Is Weakness In Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Sinqi Pharmaceutical: Report for the third quarter of 2024
Shenyang Xingqi Pharmaceutical (300573.SZ): The net income in the first three quarters was 0.291 billion yuan, a year-on-year increase of 59.47%.
On October 28th, Gelonhui, Shenyang Xingqi Pharmaceutical (300573.SZ) announced the third quarter report for 2024, achieving revenue of 1.439 billion yuan in the first three quarters, a year-on-year increase of 30.27%; net income attributable to shareholders of the listed company was 0.291 billion yuan, a year-on-year increase of 59.47%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.2897 billion yuan, a year-on-year increase of 63.31%; and basic earnings per share were 1.67 yuan.
Shenyang Xingqi Pharmaceutical (300573.SZ) released its performance for the first three quarters, with a net income of 0.291 billion yuan, a 59.47% increase.
Shenyang Xingqi Pharmaceutical (300573.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 1...
Shenyang Xingqi Pharmaceutical (300573.SZ): withdraws the registration application of proparacaine hydrochloride eye drops.
Healthcare newsletter Guolonghui reports on October 22nd that Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company recently received the "Drug Registration Application Termination Notice" issued by the National Medical Products Administration, approving the company's withdrawal of the registration application for Proparacaine Hydrochloride Eye Drops. In December 2023, the company submitted a generic drug application for Proparacaine Hydrochloride Eye Drops to the National Medical Products Administration and was accepted. The declared indication is: for ophthalmic local anesthesia. Due to policy and regulatory changes and combining market registration declaration status with the company's R&D strategy, after careful consideration, the company decided to voluntarily withdraw.
Shenyang Xingqi Pharmaceutical (300573.SZ): has cooperated with jd.com, Alibaba, baidu internet hospitals and other platforms.
Gelonghui October 22nd, shenyang xingqi pharmaceutical (300573.SZ) stated on the investor interaction platform that its subsidiary, Shenyang Xingqi Eye Hospital, has launched an internet hospital platform. The company has cooperated with jd.com, Alibaba, baidu and other internet hospital platforms. We hope that by cooperating with internet platforms, we can meet the diverse medication needs of patients.
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% HigherNo Data
No Data
